Similarly, while early senescent glioblastoma cells were killed by selective BCL-2 inhibition—although no proliferating control cells were included in the assay [62], late senescent glioblastoma cells were insensitive to BCL-2 inhibition and depended solely on BCL-xL for their survival [63]. The gene discussed is BCL2; the disease is glioblastoma.